公开(公告)号：US20240209067A1

公开(公告)日：2024-06-27

申请号：US18425919

申请日：2024-01-29

申请人： MEDIMMUNE, LLC ,  HUMABS BIOMED SA

发明人： Ebony BENJAMIN ,  Nicole KALLEWAARD-LELAY ,  Josephine Mary MCAULIFFE ,  Frances PALMER-HILL ,  Leslie WACHTER ,  Andy YUAN ,  Qing ZHU ,  Davide CORTI ,  Antonio LANZAVECCHIA ,  Barbara GUARINO ,  Anna DEMARCO

IPC分类号： C07K16/10 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/00 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C12P21/00 ,  G01N33/569 ,  G01N33/577

CPC分类号： C07K16/1018 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  C12P21/005 ,  G01N33/56983 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/11

摘要： The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

公开(公告)号：US12016925B2

公开(公告)日：2024-06-25

申请号：US17666529

申请日：2022-02-07

申请人： Medgaea Japan Co., Ltd. ,  Medgaea Life Sciences Ltd.

发明人： Chang-Jer Wu ,  Bo-Rui Chen ,  Chih-Chun Hong ,  Yuh-Ting Huang ,  Masahiko Iha ,  Makoto Tomori

IPC分类号： A61K47/26 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7012 ,  A61P17/00

CPC分类号： A61K47/26 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7012 ,  A61P17/00

摘要： A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided.

公开(公告)号：US11932682B2

公开(公告)日：2024-03-19

申请号：US17507482

申请日：2021-10-21

申请人： MEDIMMUNE, LLC ,  HUMABS BIOMED SA

发明人： Ebony Benjamin ,  Nicole Kallewaard-LeLay ,  Josephine Mary McAuliffe ,  Frances Palmer-Hill ,  Leslie Wachter ,  Andy Yuan ,  Qing Zhu ,  Davide Corti ,  Antonio Lanzavecchia ,  Barbara Guarino ,  Anna DeMarco

IPC分类号： A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C07K16/10 ,  C12P21/00 ,  G01N33/569 ,  G01N33/577 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  C12P21/005 ,  G01N33/56983 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/11 ,  A61K39/3955 ,  A61K2300/00 ,  A61K31/215 ,  A61K2300/00 ,  A61K31/7012 ,  A61K2300/00 ,  A61K31/13 ,  A61K2300/00

摘要： The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

公开(公告)号：US11813271B2

公开(公告)日：2023-11-14

申请号：US17916104

申请日：2021-03-31

申请人： LifeScience AS

发明人： Jan Remmereit

IPC分类号： A61K31/7012 ,  A61P31/14

CPC分类号： A61K31/7012 ,  A61P31/14

摘要： The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

公开(公告)号：US20220088046A1

公开(公告)日：2022-03-24

申请号：US17478185

申请日：2021-09-17

申请人： MVRIX Co., Ltd.

发明人： Woo Jae Chung ,  Dae Hyuk Kweon ,  Jinhyo Chung ,  Caleb Hong

IPC分类号： A61K31/7012 ,  A61K47/54 ,  A61P31/12

摘要： Disclosed is a viral receptor that contains a sialic acid compound at one side thereof to provide binding affinity to a virus, and contains a lipid at the other side thereof, and that can be widely used for the treatment of viral infections based on this characteristic.

公开(公告)号：US20220031720A1

公开(公告)日：2022-02-03

申请号：US17296504

申请日：2019-11-21

申请人： RAMOT AT TEL-AVIV UNIVERSITY LTD.

发明人： Vered PADLER-KARAVANI ,  Eliran Moshe REUVEN ,  Shani LEVIATAN BEN-ARYE

IPC分类号： A61K31/7012 ,  A61K9/127 ,  A61K39/39 ,  A61K39/00 ,  A61P35/00 ,  A61K39/395

摘要： The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.

公开(公告)号：US20210340214A1

公开(公告)日：2021-11-04

申请号：US17271792

申请日：2019-08-28

申请人： FIVE PRIME THERAPEUTICS, INC.

发明人： Sandeep P. INAMDAR ,  Kristen PIERCE ,  Hong XIANG ,  Susannah D. BARBEE

IPC分类号： C07K14/705 ,  A61P35/00 ,  A61K9/00 ,  A61K31/7012 ,  C07K16/18

摘要： The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.

公开(公告)号：US20210252031A1

公开(公告)日：2021-08-19

申请号：US17306614

申请日：2021-05-03

申请人： Curemark, LLC

发明人： Joan M. Fallon ,  Richard Feltenstein

IPC分类号： A61K31/7016 ,  A61K31/045 ,  A61K31/7012 ,  A61K31/047

摘要： A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

公开(公告)号：US20210220378A1

公开(公告)日：2021-07-22

申请号：US16755410

申请日：2018-10-11

申请人： LifeScience AS

发明人： Jan Remmereit ,  Hogne Vik

IPC分类号： A61K31/7012 ,  A61K9/00 ,  A61K9/08 ,  A61P31/16 ,  A61P11/02 ,  A61M11/00 ,  A61K47/10 ,  A61K47/36

摘要： The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NANA are provided for treating or preventing viral infections, such as those causing the common cold.

公开(公告)号：US11000569B2

公开(公告)日：2021-05-11

申请号：US16073860

申请日：2017-01-20

申请人： Shandong Zhonghai Pharmaceutical CO. LTD

发明人： Qian Cheng ,  Baozhen Xu ,  Long Cheng

IPC分类号： A61K38/16 ,  A61K31/715 ,  A61P1/16 ,  A61K31/7012 ,  A61K36/05 ,  A61K36/752 ,  A61K36/315 ,  A61K36/02 ,  A61K36/03 ,  A61K36/04 ,  A61K36/896 ,  A61K31/4025

摘要： A medicament for use in treating fatty liver, hepatitis and cirrhosis, the medicament includes a marine algal glycoprotein.